rRandomized trial of UDCA in PBC@` 9@e 3 Apr 2009 09:37idryentryimeeventtimeptreatbinpstageimelbiliimeeetypeimet_datewtee_datee%9.0g%tdg%tdg%9.0g%9.0g%9.0g%9.0g%4.2fventeventventPatient IDe udca, replaceDate of enrollmentudca, replaceDate of first event or loss to follow-upreplace0=placebo 1=UDCAnt or loss to follow-upreplacehistologic stage: 0=stage 1/2 at entry 1=stage 3/4placelog(bilirubin value)tage 1/2 at entry 1=stage 3/4placeEvent type (see notes)ge 1/2 at entry 1=stage 3/4placeObservation weightes)ge 1/2 at entry 1=stage 3/4place_dta2': 5 = ascites; 6 = encephnote3|PUEvent type: 5 = ascites; 6 = encephalopathy; 7 = doubling of bilirubin; 8 = worsening of symptom score by 2D_dta2': 5 = ascites; 6 = encephnote0|PU3_dta2': 5 = ascites; 6 = encephnote2|PUEvent type: 1 = death; 2 = liver transplant; 3 = histologic progression; 4 = appearance of esophogeal varices_dta2': 5 = ascites; 6 = encephnote1|PUSource: Lindor, K.D. et al. 1994. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106: 1284-1290.H_dta2': 5 = ascites; 6 = encephst_enexpPUentryE_dta2': 5 = ascites; 6 = encephReS_iE$idF_dta2': 5 = ascites; 6 = encephReS_verF$v.2G_dta2': 5 = ascites; 6 = encephReS_jG$typeD_dta2': 5 = ascites; 6 = encephReS_strD$0H_dta2': 5 = ascites; 6 = encephReS_XijH$etype!F(?F?!F`8FA?A?!F(?Fr1?!F&FF>?!F(?F1=?!F-FF>@?!F(?Fw?"F.F?@?"F.F?@?"F.F?@?"F.F?A? "FX:FQ>? "F-Fr1@? P"F(?FA?? h"F3F8?@? h"F3F8?A? 4"F\2Fr1A?d"F (FF>@?"F(?F?"F(?FT>?"FP.Fd@@?"F(F:>@?"F(F:>A?"F(?FXI??"F\3FsҘ?@?"F/FQ?@@?"F(?FA??"F,:Fr1?#F.F?@?#F:Fw@? #F(F@?#F.FQ>@@?#F,FE~?@? #F-F@@? #F-F@?d#F.F=?@?#F(?FT>? #F(?F?!#F(?FF>?"#F(?F?##F:Fr1@?$#F(?Fd?%#F(?FE׽?& $F(?FT>?'$F(?FE׽?($$FD:FF>@?)($F/F9U?@?*,$F;Fw@@?+\$F-Fr1?,\$FX*FT>@?-|$F(?Fd?.|$F/F>??/$F(?Fw?0$F(?F@@?1$F(?FA??2$F|/FqH?@@?3$F5FdA?4$FL*Fw??5$F2Fd@?5$F2FdA?6$F5F=?@?6$F5F=?A?7$F(?Fw?8$F'F@@?9%FH-Fj@UUUUUU?9%FH-Fj@@UUUUUU?9%FH-Fj@UUUUUU?:%F(?Fr1?;%F,:F?<%F,5FQ>@?<%F,5FQ>@?= %F6Fh??> %F|0F1=@@?> %F|0F1=@??$%F%F1=??@$%F;F@?A%FX*FQ?@?B%F,F=?@?C@%F*F@%+@A?D$F(?F>?E%F<3Fj?F%F`*Fr??G%F(?Fr1?H%F)Fp(@?I0&F )F?J&F2Fkw??K&F=Fsw?@?L&F(?F?M,'F2FT>@?NP'F(?Fd?OP'F(?F`??Pl'F(?Fr1?Ql'Fp4Fr1@?Rp'F(?Fj?S'F:FF>?T'F ,FU@??U'F8F1=?V'F8Fr1?W'F(?FE׽?X'F(?Fr1?Y,(F(?Fj??Z0(F(?FqH??[.F(?F?\D(F@9F?@?\D(F@9F?@?]8(F(?Fd?^8(F(?F?_L(F(?F:>?`T(F 4FP$?@?a(F9Fw?b(F(?FT>?c(F4F ?@?d(F(?F|J@?e(F(?F?f(F 0F??g(F4Fr1A?h(F40Fʃ???i)F(?Fr1?j)FL8Fr???kl)FP/FT>@?l)F2FZ?@?m)F(?F1=?n)F5F@@?o)F(?Fw?p)F5F>@@?q)F;Fj?r)FD.FE׽?s)F(?F?t*F5F:>@@UUUUUU?t*F5F:>@UUUUUU?t*F5F:>@UUUUUU?uX*F5F?v|*F(?F*@?w*FT3F1=??x*F(?F8??y*F(?F?z+F+Fw?{+F(?F?| +F(?F8??}$+F7Fw@@?~|+F3Fd?+F(?F?+FH=Fʃ??+F(?Fr1?+F(?Fr1?$,F(?Fr1?<,F05Fr??T,F(?Fw?l,F(?FP$??`,F7F`?@?p,F7FE׽@?,F@9Fr1@@?,F(?F?,F9F1?@@?,F9F1?@?8-F(?F1=?-F(?FQ>?-F(?Fj?0.F:F@?8.F3F:>@?8.F(?F>?4.F<;FA?P.F(?Fr1?.F(?F?.F(?Fr1?0/F4:F@?p,Ffp,F?.F$1FA?@?-F1Fd?/F\9Fٰ?@@?/F\9Fٰ?@?/F(?Fj?`0F(?Fr1?d0F:FE~?@?`0F(?Fw?0F`6Fr1?@?0F0;F>@?0F0;F>A?0F(?Fw?1F(?F/y??(1F=Fj@@?H1F(?F ??d1F=FA?@?1F(?Fr1?1F>FA?D2F(?FE׽?2F(?F?2F(?Fj?eventq3vlfW @ &.3:censoreddeathtranshistprogvaricesascitesencebili_2worse